{'fraction_non_alphanumeric': 0.03590664272890485, 'fraction_numerical': 0.0017953321364452424, 'mean_word_length': 6.287581699346405, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Multimodal Imaging-Guided Photothermal Immunotherapy Based on a Versatile NIR-II Aggregation-Induced Emission Luminogen.

Synergistic photothermal immunotherapy has captured extensive attention given the mutually strengthening therapeutic outcomes towards both original tumor and abscopal tumor. Herein, a versatile theranostic agent with aggregation-induced emission tendency, namely TPA-BT-DPTQ, is elaborately designed and prepared by recommending benzo[c]thiophene unit as a building block, and allows to simultaneously possess fluorescence imaging (FLI) in the second near-infrared (NIR-II) window, photoacoustic imaging (PAI), photothermal imaging (PTI), and thermal tumoricidal functions. Further experiments validate that TPA-BT-DPTQ nanoparticles-mediated photothermal therapy (PTT) can not only remarkably destroy primary tumor but also enhance the immunogenicity for further suppressing the growth of tumor in the distant sites. Furthermore, PTT combining programmed death-ligand 1 (PD-L1) antibody prominently prevent the metastasis and recurrence of cancer by potentiating the effect of immunotherapy.